Hepatocellular Carcinoma Clinical Trials in Ningbo
2 recruitingNingbo, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 3
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Hepatocellular Carcinoma
AstraZeneca210 enrolled32 locationsNCT05557838